Message From Intellia’s CEO
Every day, more than 200 researchers and staff come to work at Intellia. We are motivated by our mission to develop curative genome editing treatments for people living with severe diseases.
Many of us pursuing work in the biotechnology industry are inspired by the loss of a loved one or someone in our community who is living with a disease. We know that rare and genetic diseases, as well as cancers, not only affect the people living with the often-debilitating and life-threatening symptoms, but also significantly impact their families, friends and caregivers.
Since the emergence of the breakthrough genome editing technology, CRISPR / Cas9, the science has moved fast in only a few years. Our researchers have worked tirelessly to harness this tool for human therapeutic use. We at Intellia are humbled to have a hand in making what I believe to be medical history. As a leader in this space, we take this responsibility to patients seriously, as we advance relentlessly toward clinical trials.
I invite you to learn more about this revolutionary technology and how Intellia intends to develop one-time curative treatments to transform lives.
